Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tideglusib in Congenital or Childhood Onset DM1 (REACH CDM X)
NCT05004129Phase 3Recruiting
- Sponsor
- AMO Pharma Limited
- Start
- Aug 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of tideglusib in myotonic dystrophy type 1 (DM1), sponsored by AMO Pharma Limited. Started Aug 2021; status: recruiting.
02
Drugs
tideglusib
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT05004129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004129.